

Learning Objectives for September 2010 CE at Sea

ACPE #0129-0000-10-014-L01-P 0.1 CEU

Influenza: Lessons Learned from Pandemic H1N1 and Strategies for Seasonal Influenza 2010-2011

Donald Bennett, R.Ph., MBA, Quality Resource Manager, Pharmacy Systems, Inc., Dublin, OH

At the completion of this activity, the participant will be able to:

1. Describe the impact of pandemic Influenza Type A H1N1 on the U.S. population;
2. List three strategies that were successful with the H1N1 Influenza Vaccine production, distribution and administration plans;
3. List two actions that can be implemented to improve the plan if needed in the future; and
4. State the appropriate response to frequently asked questions related to the 2010-2011 seasonal influenza vaccine.

ACPE #0129-0000-10-015-L01-P 0.1 CEU

New Drugs: A Pharmacologist's Examination of Treatment Strategies; Then and Now

Thomas A. Gossel, R.Ph., Ph.D., Professor Emeritus, Ohio Northern University, Ada, OH

At the completion of this activity, the participant will be able to:

1. Identify therapeutic uses and applications of the new drugs in review;
2. Compare therapeutic strategies advocated during the past 70 years for treating specific pathologies addressed by the new drugs;
3. Recognize the potential for and the identity of specific drug-induced toxicity over the past 70 years relevant to therapy of specific pathologies; and,
4. Discuss potential directions to proceed in development of new drugs for the future.

ACPE #0129-0000-10-016-L01-P 0.1 CEU

A New Look at Two Old Adversaries: Diabetes Mellitus Type 2 and Hypercholesterolemia

Thomas A. Gossel, R.Ph., Ph.D., Professor Emeritus, Ohio Northern University, Ada, OH

At the completion of this activity, the participant will be able to:

1. Describe the physiologic and pathologic connections between diabetes mellitus type 2 and hypercholesterolemia;
2. List notable advancements in pharmacotherapy to manage these two adversaries and state their pharmacologic and toxicologic principles;
3. Evaluate the efficacy of the new therapeutic tools in reducing their targeted pathology and improving treatment outcomes; and
4. Demonstrate the ability to select appropriate therapy for maximizing treatment outcomes in specific patients.

ACPE #0129-0000-10-017-L01-P 0.1 CEU

Heart Health: the Mediterranean Diet and Medication Use

Donald Bennett, R.Ph., MBA, Quality Resource Manager, Pharmacy Systems, Inc., Dublin, OH

At the completion of this activity, the participant will be able to:

1. List three modifiable risk factors for decreasing the incidence of heart disease;
2. Identify four major components of the Mediterranean Diet that contributes to heart health;
3. Describe the potential benefits of moderate consumption of wine when incorporated into a healthy diet; and
4. Summarize the medication strategies used to reduce the risk of heart disease.

ACPE #0129-0000-10-018-L01-P` 0.1 CEU

Advances in Women's Healthcare

Suzanne Eastman Wuest, R.Ph., M.S., Catalina Health Resource, Cincinnati, OH

At the completion of this activity, the participant will be able to:

1. Differentiate between the various HPV vaccines;
2. Demonstrate an understanding of the prevention and treatment of breast cancer; and
3. Exhibit knowledge of women's health topics making news headlines.

ACPE #0129-0000-10-019-L01-P 0.1 CEU

Oral Chemotherapy – A New Challenge in Patient Adherence

Curtis Black, R.Ph., Ph.D., Professor of Clinical Pharmacy, University of Toledo College of Pharmacy, Toledo, OH

At the completion of this activity, the participant will be able to:

1. Identify new oral therapies for the treatment of malignant cancers;
2. Describe how oral therapies are prescribed as part of cancer treatment regimens;
3. State how common adverse effects influence patient adherence to prescribed regimens; and
4. Employ strategies that will address patient concerns and common problems associated with non-adherence to prescribed therapy .

ACPE #0129-0000-10-020-L04-P 0.1 CEU

Pharmacists and Legislation: Making YOUR Input Count

Ernie Boyd, R.Ph., CAE, OPA Lobbyist

At the completion of this activity, the participant will be able to:

1. Identify the latest federal legislative and regulatory issues that impact the practice of pharmacy;
2. Describe effective means of contacting legislators to express specific concerns about issues affecting pharmacy practice; and

3. Outline how to shape communications to impact legislative issues through grassroots activity.

ACPE #0129-0000-10-021-L04-P

Federal Mandates for Consumer Information: Implications for Pharmacists

J. Richard Wuest, R.Ph., PharmD, Professor Emeritus, University of Cincinnati, Cincinnati, OH

At the completion of this activity, the participant will be able to:

1. Demonstrate an understanding of the materials that governmental agencies and private groups are supplying to patients;
2. Exhibit knowledge of current and proposed approved labeling for nonprescription medications;
3. Differentiate between Medication Guides, Patient Package Inserts (PPIs), Package inserts (PIs) and Consumer Medication Information (CMI).

ACPE #0129-0000-10-022-H01-P 0.3 CEU

New Drugs 2009: Afinitor, Coartem, Dysport, Fanapt, Samsca and Simponi

Thomas A. Gossel, R.Ph., Ph.D., Professor Emeritus, Ohio Northern University, Ada, OH
J. Richard Wuest, R.Ph., PharmD, Professor Emeritus, University of Cincinnati, Cincinnati, OH

At the completion of this activity, the participant will be able to:

1. Differentiate the new drugs by generic name, trade name and chemical name when relevant;
2. Identify the indication(s), pharmacologic action(s) and significant pharmacokinetic principles of the drugs;
3. Recognize important therapeutic uses for the drugs and their applications in specified pathologies; and
4. Demonstrate an understanding of adverse effects and toxicity, and significant drug-drug interactions.